Access count of this item: 172

Files in This Item:
File Description SizeFormat 
16_0489.pdf4.38 MBAdobe PDFView/Open
Title: 19-norhydroxyprogesterone caproate(SH-582)による前立腺肥大症の治療について
Other Titles: Treatment of prostatic hypertrophy with 19-norhydroxyprogesterone caproate
Authors: 加藤, 篤二  KAKEN_name
岡田, 謙一郎  KAKEN_name
Author's alias: Kato, Tokuji
Okada, Ken-ichiro
Keywords: Aged
Animals
Caproates/pharmacology/therapeutic use
Humans
Injections, Intramuscular
Male
Middle Aged
Organ Size
Pregnanes/pharmacology/therapeutic use
Prostate/drug effects/pathology
Prostatic Hyperplasia/drug therapy
Rats
Seminal Vesicles/drug effects/pathology
Testis/drug effects/pathology
Issue Date: Sep-1970
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 16
Issue: 9
Start page: 489
End page: 500
Abstract: 1) SH-582 was used in 25 cases of prostatic hypertrophy over an average period of 5 months. Clinical symptoms were improved in 60 to 70 % of those cases. 2) Animal experiments in rats demonstrated an atrophy of the ventral lobe of the prostate. 3) It was presumed that the effects of SH•582 in reducing the prostate might be ascribable to its inhibitory action not on the central but on the peripheral system, or, to be more accurate, on the prostate itself. 4) There were no severe side-effects following administration of SH-582. However, great care should be taken when patients having complications of diabetes or hepatic disturbances are treated with SH-582.
URI: http://hdl.handle.net/2433/121163
PubMed ID: 4097361
Appears in Collections:Vol.16 No.9

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.